Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL; HCV Research UK. Cheung MCM, et al. Among authors: macdonald dc. J Hepatol. 2016 Oct;65(4):741-747. doi: 10.1016/j.jhep.2016.06.019. Epub 2016 Jul 5. J Hepatol. 2016. PMID: 27388925 Free article.
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5. J Hepatol. 2017. PMID: 28789880 Free article. No abstract available.
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12. J Hepatol. 2018. PMID: 29339112 Free article. No abstract available.
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
Hamill V, Wong S, Benselin J, Krajden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velásquez García HA, Yeung A, Johnson P, Barclay ST, Alvarez M, Toyoda H, Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson P, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha IN, Irving WL, Janjua NZ, Innes H. Hamill V, et al. BMJ. 2023 Aug 2;382:e074001. doi: 10.1136/bmj-2022-074001. BMJ. 2023. PMID: 37532284 Free PMC article.
Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy.
Wang T, Campbell C, Stockdale AJ, Todd S, McIntyre K, Frankland A, Jaworski J, Glampson B, Papadimitriou D, Mercuri L, Mayer E, Jones CR, Salih H, Roadknight G, Little S, Noble T, Várnai KA, Davis C, Heinson AI, George M, Borca F, English L, Romão L, Ramlakhan D; NIHR HIC Viral Hepatitis and Liver Disease Consortium; Woods K, Davies J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Barnes E, Matthews PC. Wang T, et al. JHEP Rep. 2024 Oct 9;7(1):101229. doi: 10.1016/j.jhepr.2024.101229. eCollection 2025 Jan. JHEP Rep. 2024. PMID: 39717508 Free PMC article.
44 results